Booth Andrew 4

What Happened
Andrew Booth, Chief Financial Officer of AbCellera Biologics (ABCL), exercised stock options on June 3, 2026. He acquired 250,000 shares at $0.19 per share for a total cash outlay of $47,500. The filing also shows a concurrent disposition of 250,000 shares at $0.00 (reported as a derivative disposition).

Key Details

• Transaction date: 2026-06-03. Transaction code M = option exercise/conversion.
• Acquired: 250,000 shares at $0.19 each; total $47,500.
• Disposed: 250,000 shares at $0.00 (derivative) — reported proceeds $0.
• Shares owned after transaction: not disclosed in the filing.
• Footnote: These options vest in substantially equal annual tranches over a six-year period, with the first tranche vested June 15, 2017 (see F1).
• Filing timeliness: Reported on 2026-06-03 (same-day filing), so not marked late.

Context

• Transaction code M denotes an exercise/conversion of derivative securities (options). The reported $0.00 disposition is not an open‑market sale; filings commonly show $0 dispositions when shares are surrendered to cover exercise costs or tax withholding.
• This was an option exercise rather than a market sale — exercises are routine and do not necessarily signal a view on the company’s near-term stock direction.